Hub : Traits :

Gout (self-reported)

225 significantly associated models · 62 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 2 26592429 28607344 19 1 6.0e-28 3.8e-28 1.00000 100 FNDC4
2 3 52174970 53623102 2 1 1.8e-09 1.6e-10 0.02980 88 SFMBT1
3 4 9370814 11156010 4 9 3.2e-70 2.9e-88 NaN NaN RP11-448G15.3 SLC2A9 WDR1
4 4 87655053 89947462 7 13 3.8e-123 1.5e-197 NaN NaN ABCG2 HERC6 NUDT9 PKD2 PPM1K RP11-10L7.1 SPP1
5 5 72171715 72675238 1 1 1.7e-08 1.7e-08 1.00000 100 TMEM171
6 6 25266147 26689223 3 1 1.1e-16 9.4e-20 0.00015 83 U91328.21
7 7 71935903 73738067 2 1 6.1e-12 5.0e-12 1.00000 100 MLXIPL
8 10 60712592 62185494 1 1 4.8e-11 6.6e-13 0.00367 84 SLC16A9
9 11 63305184 66262606 7 7 6.8e-26 4.5e-21 NaN NaN CCDC88B NRXN2 OVOL1 SLC22A11 SLC22A12 VEGFB
10 12 56776586 58705075 4 1 4.6e-13 1.2e-14 0.00738 88 INHBC
11 12 121820692 123326374 1 1 5.0e-10 1.0e-10 1.00000 100 MLXIP
12 15 75444033 76878362 1 1 6.4e-09 1.5e-06 0.58700 99 UBE2Q2
13 15 90385311 90891982 1 1 1.1e-08 1.1e-08 1.00000 100 IDH2
14 16 69112398 70669292 1 1 2.3e-07 6.1e-08 0.05250 87 WWP2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 0.89 1 0 0.0 0.00 1.0e+00 FNDC4
Bipolar Disorder or Schizophrenia 1.02 1 0 0.0 0.00 1.0e+00 U91328.21
Depressed Affect (Nagel 2018) 0.95 1 0 0.0 0.00 1.0e+00 CCDC88B
Intelligence (Savage-Jansen 2018) 0.99 1 1 2.2 0.00 1.0e+00 SFMBT1
Neuroticism (Nagel 2018) 0.78 1 0 0.0 0.00 1.0e+00 SFMBT1
Schizophrenia (2018) 1.21 1 0 0.0 0.00 1.0e+00 MLXIP
Schizophrenia vs Biploar Disorder 1.27 1 0 0.0 0.00 1.0e+00 FNDC4
Worry (Nagel 2018) 1.10 2 0 0.0 0.00 1.0e+00 PKD2 SFMBT1
Crohns Disease (2017) 1.45 2 1 2.2 0.00 1.0e+00 CCDC88B FNDC4
Irritable Bowel Disease (IBD) 0.91 1 1 2.2 0.00 1.0e+00 FNDC4
Verbal and Numeric Reasoning (VNR) 1.17 2 0 0.0 0.00 1.0e+00 SFMBT1 WWP2
Breast Cancer 2.46 2 1 2.2 0.95 5.1e-02 ABCG2 PPM1K
Crohns Disease (2012) 1.56 2 0 0.0 0.00 1.0e+00 CCDC88B FNDC4
Fasting Glucose 3.00 1 1 2.2 0.00 1.0e+00 FNDC4
HDL Cholesterol 1.61 2 1 2.2 0.00 1.0e+00 INHBC MLXIPL
LDL Cholesterol 1.14 1 0 0.0 0.00 1.0e+00 FNDC4
Primary Biliary Cirrhosis 1.44 1 0 0.0 0.00 1.0e+00 CCDC88B
Triglycerides 14.79 3 3 6.7 0.00 1.0e+00 FNDC4 INHBC MLXIPL
Ulcerative Colitis 1.14 1 0 0.0 0.00 1.0e+00 SFMBT1
Blood Eosinophil Count 0.88 3 2 4.4 0.00 1.0e+00 MLXIPL OVOL1 WWP2
Blood Platelet Count 1.89 8 4 8.9 0.71 5.0e-02 FNDC4 INHBC MLXIP MLXIPL NUDT9 OVOL1 SLC2A9 UBE2Q2
Blood Red Count 1.01 7 5 11.1 -0.24 6.1e-01 FNDC4 INHBC MLXIP SFMBT1 SLC2A9 UBE2Q2 WWP2
Blood White Count 1.72 4 2 4.4 0.92 7.8e-02 FNDC4 MLXIPL SLC16A9 WWP2
Heel T-Score 1.82 8 4 8.9 0.60 8.5e-02 ABCG2 CCDC88B OVOL1 PKD2 PPM1K SLC16A9 SPP1 TMEM171
BMI 2.02 9 8 17.8 -0.75 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Height 1.14 11 7 15.6 -0.60 4.1e-02 FNDC4 MLXIP MLXIPL NUDT9 OVOL1 SLC16A9 SLC2A9 SPP1 TMEM171 WDR1 WWP2
Waist Hip Ratio (WHR) 1.03 2 2 4.4 0.00 1.0e+00 MLXIP MLXIPL
Systolic Blood Pressure 0.98 4 0 0.0 0.96 4.2e-02 FNDC4 MLXIP OVOL1 SLC16A9
Smoking Status 1.03 2 0 0.0 0.00 1.0e+00 CCDC88B NRXN2
Allergy or Eczema 1.37 3 2 4.4 0.00 1.0e+00 FNDC4 MLXIP OVOL1
Cardiovascular Disease 1.40 4 1 2.2 1.00 2.5e-03 CCDC88B FNDC4 MLXIPL OVOL1
Hypothyroidism (self reported) 1.75 3 1 2.2 0.00 1.0e+00 CCDC88B MLXIP PKD2
Type 2 Diabetes (T2D) (2018) 1.84 2 1 2.2 0.00 1.0e+00 FNDC4 WWP2
Lung FEV1/FVC ratio 0.61 2 1 2.2 0.00 1.0e+00 SLC2A9 WDR1
Lung FVC 1.04 2 1 2.2 0.00 1.0e+00 SLC2A9 WWP2
Neuroticism 0.82 1 0 0.0 0.00 1.0e+00 SFMBT1
Chronotype (morning person) 0.69 1 0 0.0 0.00 1.0e+00 WWP2
Hair Pigment 0.13 4 0 0.0 0.27 7.3e-01 FNDC4 INHBC MLXIPL OVOL1
Tanning 0.33 2 1 2.2 0.00 1.0e+00 FNDC4 MLXIPL
Hand grip strength (left) 1.19 1 0 0.0 0.00 1.0e+00 WWP2
Number of treatments/medications taken 1.46 2 0 0.0 0.00 1.0e+00 FNDC4 OVOL1
Sensitivity / hurt feelings 0.89 1 0 0.0 0.00 1.0e+00 U91328.21
Relative age of first facial hair 1.38 2 1 2.2 0.00 1.0e+00 FNDC4 OVOL1
Medication: Metformin 1.09 1 1 2.2 0.00 1.0e+00 FNDC4
Diabetes (father) 1.34 1 0 0.0 0.00 1.0e+00 FNDC4
Diabetes (mother) 1.56 1 0 0.0 0.00 1.0e+00 FNDC4
Pack years adult smoking proportion 1.16 1 0 0.0 0.00 1.0e+00 SFMBT1
Impedance of leg (right) 1.50 5 2 4.4 0.88 4.7e-02 FNDC4 MLXIP MLXIPL PPM1K SPP1
Leg fat-free mass (left) 1.94 7 3 6.7 -0.86 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat percentage 1.22 4 2 4.4 -0.52 4.8e-01 MLXIP NRXN2 RP11-10L7.1 WWP2
Hand grip strength (right) 0.89 1 0 0.0 0.00 1.0e+00 WWP2
Fed-up feelings 1.28 1 0 0.0 0.00 1.0e+00 CCDC88B
Taking other prescription medications 1.63 1 0 0.0 0.00 1.0e+00 CCDC88B
Age when periods started (menarche) 1.14 1 1 2.2 0.00 1.0e+00 WWP2
Heel bone mineral density (BMD) T-score, automated (left) 1.49 3 1 2.2 0.00 1.0e+00 OVOL1 PKD2 SPP1
High blood pressure 1.14 2 0 0.0 0.00 1.0e+00 CCDC88B OVOL1
Hayfever, allergic rhinitis or eczema 1.51 3 1 2.2 0.00 1.0e+00 MLXIP OVOL1 U91328.21
Medication: Levothyroxine sodium 1.44 1 0 0.0 0.00 1.0e+00 CCDC88B
Sitting height 1.75 7 6 13.3 -0.93 2.0e-03 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21 WWP2
Body mass index (BMI) 1.75 7 2 4.4 -0.75 5.1e-02 ABCG2 FNDC4 MLXIP NRXN2 PPM1K SLC22A12 WWP2
Impedance of leg (left) 1.66 6 3 6.7 0.68 1.4e-01 FNDC4 MLXIP MLXIPL PPM1K SLC2A9 SPP1
Leg predicted mass (left) 1.93 7 3 6.7 -0.86 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat mass 1.39 5 2 4.4 -0.80 1.1e-01 ABCG2 MLXIP NRXN2 RP11-10L7.1 WWP2
Waist circumference 1.59 6 2 4.4 -0.82 4.6e-02 ABCG2 FNDC4 MLXIP PPM1K RP11-10L7.1 WWP2
Nervous feelings 1.07 1 0 0.0 0.00 1.0e+00 SFMBT1
Forced vital capacity (FVC) 1.15 3 1 2.2 0.00 1.0e+00 PKD2 PPM1K WWP2
Heel bone mineral density (BMD) T-score, automated (right) 1.50 4 1 2.2 0.98 1.6e-02 OVOL1 PKD2 PPM1K SPP1
Qualifications: None of the above 0.77 1 0 0.0 0.00 1.0e+00 SFMBT1
Heart attack 1.03 1 0 0.0 0.00 1.0e+00 INHBC
Allergy 1.21 2 1 2.2 0.00 1.0e+00 MLXIP OVOL1
Diabetes (self-reported) 1.59 1 1 2.2 0.00 1.0e+00 FNDC4
Medication: Simvastatin 1.90 1 1 2.2 0.00 1.0e+00 FNDC4
Fluid intelligence score 1.05 2 0 0.0 0.00 1.0e+00 SFMBT1 WWP2
Neuroticism score 0.88 1 0 0.0 0.00 1.0e+00 SFMBT1
Weight 1.82 6 3 6.7 -0.91 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NRXN2 U91328.21
Impedance of arm (right) 1.90 3 2 4.4 0.00 1.0e+00 FNDC4 MLXIPL SLC2A9
Arm fat percentage (right) 1.47 4 2 4.4 0.96 3.9e-02 MLXIP PPM1K RP11-10L7.1 WWP2
Trunk fat-free mass 2.21 7 5 11.1 -0.87 1.1e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Hip circumference 2.11 6 4 8.9 -0.79 6.3e-02 ABCG2 FNDC4 MLXIP MLXIPL NRXN2 WWP2
Alcohol intake versus 10 years previously 2.13 1 1 2.2 0.00 1.0e+00 FNDC4
Forced expiratory volume in 1-second (FEV1) 0.96 3 1 2.2 0.00 1.0e+00 PKD2 PPM1K WWP2
Pulse rate 1.32 1 1 2.2 0.00 1.0e+00 FNDC4
Serious illness, injury or assault of a close relative in last 2 years 1.58 1 0 0.0 0.00 1.0e+00 WWP2
Asthma 0.78 1 0 0.0 0.00 1.0e+00 U91328.21
Medication: Cholesterol lowering 1.81 1 1 2.2 0.00 1.0e+00 FNDC4
Illnesses of mother 2.07 1 0 0.0 0.00 1.0e+00 WDR1
Forced expiratory volume in 1-second (FEV1), Best measure 0.92 2 1 2.2 0.00 1.0e+00 U91328.21 WWP2
Impedance of arm (left) 2.03 3 2 4.4 0.00 1.0e+00 FNDC4 MLXIPL SLC2A9
Arm fat mass (right) 1.60 7 2 4.4 -0.76 4.8e-02 ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Trunk predicted mass 2.21 7 5 11.1 -0.86 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Standing height 1.36 9 5 11.1 -0.67 3.6e-02 FNDC4 MLXIP NUDT9 SLC16A9 SLC2A9 SPP1 TMEM171 U91328.21 WWP2
Peak expiratory flow (PEF) 0.70 1 0 0.0 0.00 1.0e+00 WWP2
Headache pain in last month 0.99 1 0 0.0 0.00 1.0e+00 NUDT9
Medication for cholesterol, blood pressure or diabetes 1.25 1 0 0.0 0.00 1.0e+00 FNDC4
Hypothyroidism/myxoedema (self-reported) 1.52 1 0 0.0 0.00 1.0e+00 CCDC88B
Medication: Amlodipine 1.39 1 0 0.0 0.00 1.0e+00 OVOL1
High blood pressure (siblings) 1.02 1 0 0.0 0.00 1.0e+00 FNDC4
Forced vital capacity (FVC), Best measure 1.18 2 1 2.2 0.00 1.0e+00 SLC16A9 WWP2
Body fat percentage 1.32 6 2 4.4 -0.70 1.2e-01 ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Leg fat percentage (right) 1.49 7 2 4.4 -0.76 4.8e-02 ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Arm fat-free mass (right) 2.22 7 4 8.9 -0.87 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Comparative body size at age 10 1.09 2 0 0.0 0.00 1.0e+00 MLXIP OVOL1
Medication: Allopurinol 44.90 27 21 46.7 1.00 4.0e-43 ABCG2 CCDC88B FNDC4 HERC6 IDH2 INHBC MLXIP MLXIPL NRXN2 NUDT9 OVOL1 PKD2 PPM1K RP11-10L7.1 RP11-448G15.3 SFMBT1 SLC16A9 SLC22A11 SLC22A12 SLC2A9 SPP1 TMEM171 U91328.21 UBE2Q2 VEGFB WDR1 WWP2
Whole body fat mass 1.52 6 2 4.4 -0.78 6.7e-02 ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Leg fat mass (right) 1.69 8 2 4.4 -0.81 1.5e-02 ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Arm predicted mass (right) 2.21 7 4 8.9 -0.86 1.3e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Pulse rate, automated reading 1.90 3 1 2.2 0.00 1.0e+00 FNDC4 MLXIPL WWP2
Alcohol intake frequency. 2.98 4 1 2.2 0.97 3.2e-02 FNDC4 MLXIPL UBE2Q2 WWP2
Comparative height size at age 10 1.43 6 3 6.7 -0.70 8.0e-02 FNDC4 MLXIP SLC16A9 SLC2A9 TMEM171 U91328.21
Number of full sisters 1.04 1 0 0.0 0.00 1.0e+00 SLC2A9
Suffer from 'nerves' 1.23 1 0 0.0 0.00 1.0e+00 SFMBT1
Supplements: Vitamin C 0.86 1 0 0.0 0.00 1.0e+00 WWP2
Hypertension (Self-reported) 1.17 2 0 0.0 0.00 1.0e+00 CCDC88B OVOL1
Forced expiratory volume in 1-second (FEV1), predicted 0.95 1 0 0.0 0.00 1.0e+00 SLC16A9
Whole body fat-free mass 2.10 7 4 8.9 -0.86 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg fat-free mass (right) 1.84 7 3 6.7 -0.86 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat percentage (left) 1.63 5 2 4.4 -0.69 2.0e-01 ABCG2 MLXIP PPM1K RP11-10L7.1 WWP2
Mood swings 1.50 1 0 0.0 0.00 1.0e+00 SFMBT1
Diabetes diagnosed by doctor 1.78 2 1 2.2 0.00 1.0e+00 FNDC4 WWP2
Qualifications: nursing, teaching 1.27 1 0 0.0 0.00 1.0e+00 SFMBT1
Medication for cholesterol 1.39 1 1 2.2 0.00 1.0e+00 FNDC4
Back pain experienced in last month 1.25 1 0 0.0 0.00 1.0e+00 NUDT9
Osteoporosis (self-reported) 1.51 1 0 0.0 0.00 1.0e+00 SPP1
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.11 1 0 0.0 0.00 1.0e+00 WWP2
Whole body water mass 2.14 7 4 8.9 -0.86 1.3e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg predicted mass (right) 1.85 7 3 6.7 -0.86 1.2e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat mass (left) 1.65 7 2 4.4 -0.76 4.9e-02 ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Number of self-reported non-cancer illnesses 1.95 2 1 2.2 0.00 1.0e+00 CCDC88B FNDC4
Medication: Blood pressure 1.47 1 0 0.0 0.00 1.0e+00 OVOL1
Pain type(s) experienced in last month: Hip pain 2.19 1 0 0.0 0.00 1.0e+00 MLXIP
High cholesterol (Self-reported) 3.56 1 1 2.2 0.00 1.0e+00 FNDC4
Medication: Lisinopril 1.05 1 0 0.0 0.00 1.0e+00 MLXIP
Medication: Atorvastatin 2.30 1 1 2.2 0.00 1.0e+00 FNDC4
Ever smoked 1.73 2 0 0.0 0.00 1.0e+00 NRXN2 SLC22A12
Basal metabolic rate 2.02 7 4 8.9 -0.88 8.9e-03 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg fat percentage (left) 1.38 7 2 4.4 -0.77 4.4e-02 ABCG2 MLXIP NRXN2 PPM1K RP11-10L7.1 SLC22A12 WWP2
Arm fat-free mass (left) 2.07 7 4 8.9 -0.86 1.3e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Diastolic blood pressure, automated reading 0.76 2 0 0.0 0.00 1.0e+00 MLXIP OVOL1
Vascular/heart problems diagnosed by doctor 1.12 3 0 0.0 0.00 1.0e+00 CCDC88B MLXIP OVOL1
Cholesterol lowering medication 2.10 1 1 2.2 0.00 1.0e+00 FNDC4
Basal cell carcinoma (self-reported) 1.05 1 0 0.0 0.00 1.0e+00 CCDC88B
Heart attack/myocardial infarction (self-reported) 1.07 1 0 0.0 0.00 1.0e+00 INHBC
Pack years of smoking 1.13 1 0 0.0 0.00 1.0e+00 SFMBT1
Impedance of whole body 1.96 6 2 4.4 0.76 7.9e-02 ABCG2 FNDC4 MLXIPL PPM1K SLC2A9 SPP1
Leg fat mass (left) 1.65 7 2 4.4 -0.81 2.7e-02 ABCG2 FNDC4 MLXIP NRXN2 PPM1K RP11-10L7.1 WWP2
Arm predicted mass (left) 2.14 7 4 8.9 -0.87 1.0e-02 ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 9 0.258 1.5
GTEx Adipose Visceral Omentum 8 0.393 1.6
GTEx Adrenal Gland 2 0.137 1.4
GTEx Artery Aorta 5 0.168 1.4
GTEx Artery Coronary 4 0.338 1.5
GTEx Artery Tibial 9 0.239 1.4
GTEx Brain Caudate basal ganglia 0 0.000 1.2
GTEx Brain Cerebellar Hemisphere 1 0.067 1.3
GTEx Brain Cerebellum 1 0.050 1.4
GTEx Brain Cortex 1 0.097 1.3
GTEx Brain Frontal Cortex BA9 0 0.000 1.3
GTEx Brain Hippocampus 0 0.000 1.3
GTEx Brain Hypothalamus 0 0.000 1.3
GTEx Brain Nucleus accumbens basal ganglia 1 0.116 1.3
GTEx Brain Putamen basal ganglia 0 0.000 1.3
GTEx Breast Mammary Tissue 2 0.101 1.4
GTEx Breast Mammary Tissue (Male) 2 0.168 1.3
GTEx Breast Mammary Tissue (Female) 1 0.061 1.4
GTEx Cells EBV-transformed lymphocytes 2 0.141 1.4
GTEx Cells Transformed fibroblasts 6 0.143 1.3
GTEx Colon Sigmoid 3 0.205 1.5
GTEx Colon Transverse 6 0.291 1.5
GTEx Esophagus Gastroesophageal Junction 2 0.138 1.4
GTEx Esophagus Mucosa 6 0.181 1.5
GTEx Esophagus Muscularis 5 0.155 1.5
GTEx Heart Atrial Appendage 0 0.000 1.3
GTEx Heart Left Ventricle 1 0.065 1.4
GTEx Liver 1 0.139 1.5
GTEx Lung 5 0.174 1.4
GTEx Muscle Skeletal 5 0.173 1.4
GTEx Nerve Tibial 9 0.208 1.4
GTEx Ovary 1 0.110 1.4
GTEx Pancreas 2 0.123 1.3
GTEx Pituitary 1 0.090 1.3
GTEx Prostate 1 0.120 1.4
GTEx Skin Not Sun Exposed Suprapubic 4 0.163 1.4
GTEx Skin Sun Exposed Lower leg 5 0.137 1.4
GTEx Small Intestine Terminal Ileum 1 0.217 1.5
GTEx Spleen 2 0.142 1.4
GTEx Stomach 0 0.000 1.3
GTEx Testis 5 0.158 1.4
GTEx Thyroid 7 0.175 1.4
GTEx Uterus 0 0.000 1.3
GTEx Vagina 1 0.157 1.5
GTEx Whole Blood 4 0.201 1.5
METSIM Adipose 7 0.152 1.4
NTR Blood 2 0.083 1.4
ROSMAP Brain Pre-frontal Cortex 10 0.228 1.4
YFS Blood 4 0.087 1.3
CommonMind Brain Pre-frontal Cortex 7 0.130 1.3
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.3
The Cancer Genome Atlas Breast Invasive Carcinoma 10 0.227 1.4
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.273 1.4
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 1.3
The Cancer Genome Atlas Esophageal Carcinoma 1 0.146 1.4
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.4
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 3 0.110 1.6
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 10 0.244 1.4
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 3 0.146 1.4
The Cancer Genome Atlas Brain Lower Grade Glioma 3 0.070 1.3
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 1 0.090 1.4
The Cancer Genome Atlas Lung Adenocarcinoma 2 0.068 1.2
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 0 0.000 1.3
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 3 0.188 1.4
The Cancer Genome Atlas Pancreatic Adenocarcinoma 2 0.120 1.4
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.3
The Cancer Genome Atlas Prostate Adenocarcinoma 7 0.151 1.3
The Cancer Genome Atlas Rectum Adenocarcinoma 1 0.145 1.3
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.2
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.4
The Cancer Genome Atlas Stomach Adenocarcinoma 2 0.119 1.3
The Cancer Genome Atlas Testicular Germ Cell Tumors 0 0.000 1.4
The Cancer Genome Atlas Thyroid Carcinoma 8 0.155 1.4
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.3